Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide

Autor: Robert E.J. Ryder, Katharina Laubner, Marek Benes, Martin Haluzik, Lynne Munro, Harry Frydenberg, Julian P. Teare, Aruchuna Ruban, Sigal Fishman, Erwin Santo, Rainer Stengel, Charlotte De Jonge, Jan W. Greve, Ricardo V. Cohen, Cristina M. Aboud, Gerald J. Holtmann, Graeme Rich, Jess J. McMaster, Tadej Battelino, Primoz Kotnik, James P. Byrne, John C. Mason, Justin Bessell, Jeanine Bascomb, Lillian Kow, Janes Collins, Jacob Chisholm, Peter N. Pferschy, Harald Sourij, Melissa L. Cull, Melanie C. Wyres, Russell Drummond, Barbara McGowan, Stephanie A. Amiel, Mahi Yadagiri, Piya Sen Gupta, Jens Aberle, Jochen Seufert

Publikováno v: Diabetes Care. 46:e89-e91

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dab10af8e13494185d21848d0f3e18f3
https://doi.org/10.2337/dc22-1952

Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Autor: Carolina Solis-Herrera, Robert E.J. Ryder, Devjit Tripathy

Publikováno v: Diabetes Spectr

Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72fed929e530b07fb7a1b0ba60be6e3e
https://doi.org/10.2337/ds20-0078

1415-P: Risk–Benefit Data from the Worldwide EndoBarrier (EB) Registry

Autor: ROBERT E.J. RYDER, JULIAN P. TEARE, ARUCHUNA RUBAN, MARTIN HALUZIK, LYNNE MUNRO, HARRY FRYDENBERG, JESSICA J. MCMASTER, SIGAL FISHMAN, RAINER STENGEL, RICARDO V. COHEN, CRISTINA M. ABOUD, JAMES P. BYRNE, GERALD J. HOLTMANN, CHARLOTTE DE JONGE, JAN WILLEM GREVE, JOHN C. MASON, JUSTIN BESSELL, LILIAN KOW, HARALD SOURIJ, PETER N. PFERSCHY, MELISSA L. CULL, MELANIE C. WYRES, RUSSELL DRUMMOND, BARBARA MCGOWAN, STEPHANIE A. AMIEL, MAHENDER YADAGIRI, PIYA SEN GUPTA, KATHARINA LAUBNER, JOCHEN SEUFERT

Publikováno v: Diabetes. 71

Uncertainty exists re risk:benefit of proximal intestinal exclusion with EB, a novel endoscopic duodenal jejunal liner device for obesity, both with and without diabetes. In view of this, during 2017, an independent, secure, on line registry was esta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5abec677b0d7dcff610c03942419351
https://doi.org/10.2337/db22-1415-p

An audit of people admitted to hospital with diabetes and coronavirus (SARS-CoV-2): data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit

Autor: Kinga A Várnai, Robert E.J. Ryder, Dinesh Nagi, Yue Ruan, Sophie Harris, Parth Narendran, Emma G. Wilmot, Sarah H. Wild, Jim Davies, Rustam Rea, Kamlesh Khunti, Benjamin C. T. Field, Rajiv Gandhi

Publikováno v: Nagi, D, Ryder, R EJ, Ruan, Y, Field, B CT, Narendran, P, Gandhi, R, Harris, S, Varnai, K A, Davies, J, Wild, S H, Wilmot, E G, Khunti, K & Rea, R 2021, ' An audit of people admitted to hospital with diabetes and coronavirus (SARS-CoV-2) : data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit ', British Journal of Diabetes, vol. 21, no. 1 . https://doi.org/10.15277/bjd.2021.299

We describe the rationale, aims and objectives and the methodology of data collection for the ABCD nationwide audit of individuals admitted to hospital with coronavirus (SARS-CoV-2; COVID-19) and diabetes. The audit was inspired and undertaken by the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f2559bbc12204639aed8b56a4afb59
https://doi.org/10.15277/bjd.2021.299

Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit

Autor: Ken Darzy, Thomas Sj Crabtree, Anurita Rohilla, Iskandar Idris, Abcd Canagliflozin Audit Contributors, Rajeev Raghavan, Alex Bickerton, Alison Evans, Peter H. Winocour, Robert E.J. Ryder, Mahender Yadagiri, Suzanne Phillips, Devesh K. Sennik

Publikováno v: British Journal of Diabetes. 20:113-116

Introduction: Canagliflozin was initially approved for use in the UK in March 2013. Randomised control trial evidence has demonstrated multiple beneficial effects. Many of these are present at initial follow-up and within 26 weeks of randomised contr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d8d8ea9105274ba697d46acfaba5417c
https://doi.org/10.15277/bjd.2020.258